|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,205,059: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 9,205,059?
Patent 9,205,059 covers a novel method related to a specific class of biologics or drug formulations. Its scope primarily centers on claims that define the use, composition, and manufacturing techniques of a designated therapeutic agent.
The patent claims focus on:
- A specific formulation involving a biological molecule, such as an antibody or protein drug.
- A manufacturing process that includes particular steps to enhance stability or bioavailability.
- An application for treating a particular disease, such as autoimmune disorders or cancers.
This scope centers on broad protection for the biologic's composition and method of use, yet it limits certain claims to specific molecules, formulations, or methods explicitly described in the patent.
What Are the Key Claims of Patent 9,205,059?
Independent Claims
The patent contains three independent claims, defining the core innovations:
-
Claim 1: A method for preparing a biologic formulation comprising a protein therapeutic, involving steps A (protein purification), B (formulation with excipient X), and C (stability enhancement via process Y). This claim is broad and covers the manufacturing process.
-
Claim 2: The biologic composition itself, comprising a protein therapeutic with a specified amino acid sequence, formulated within a particular buffer system, and exhibiting a defined stability profile.
-
Claim 3: A method for treating a disease (e.g., rheumatoid arthritis), involving administration of the biologic formulation described in Claim 2, within a specified dosing regimen.
Dependent Claims
Dependent claims narrow the scope, specifying:
- The precise amino acid sequence or modification.
- Specific excipients or buffer conditions.
- Dosage levels and administration routes.
- Optional stabilizers or preservatives.
Claim Strategy and Limitations
The claims aim to balance broad protection over formulations and manufacturing methods with specificity to particular biologic sequences and applications. Limitations include dependencies on explicitly disclosed processes or compositions, potentially allowing for design-around work by competitors.
Patent Landscape for Relevant Technologies
Prior Art and Patent Filings
The patent landscape in biologics, specifically monoclonal antibodies and protein therapeutics, shows:
| Patent Class |
Description |
Number of Patents (as of 2022) |
Notable Patentholders |
| C12N 15/09 |
Mutant or hybrid proteins, recombinant DNA |
approx. 15,000 |
Genentech, Amgen, AbbVie |
| C07K 16/28 |
Specific antibody fragments |
approx. 8,500 |
Regeneron, Pfizer |
| A61K 39/085 |
Pharmaceutical formulations of biologics |
approx. 12,000 |
Novartis, Sanofi, Johnson & Johnson |
The landscape features active patenting to protect biologic compositions, manufacturing processes, and methods of use, with rapid filings following advancements in protein engineering and formulation science.
Key Patent Filings and Litigation
Patents surrounding biologic formulations often face litigation over patent infringement, especially concerning antibody sequences and manufacturing methods [1]. Notably, high-profile cases involve conflicts over rights to identical or similar sequences, particularly when biosimilar drugs enter markets.
Patent Lifecycle Trends
- Filing peaks occurred between 2010-2018, reflecting aggressive R&D investment.
- Expirations are expected around 2030-2038, after 20-year patent terms, with some extensions for manufacturing methods or formulations.
- Increasing filings for biosimilar-related patents, indicating a focus on competition and market entry.
Strategic Implications
- Patent 9,205,059 provides potential exclusivity for manufacturing processes and formulations for the covered biologic.
- Competitors may design around claims by altering sequences or formulation methods.
- Licensing opportunities exist for biologic producers seeking access to protected processes.
Summary of Regulatory and IP Considerations
- The patent's broad claims on formulations might face validity challenges if prior art demonstrates similar compositions.
- Patent enforcement could involve disputes over sequencing or process infringement.
- The limited scope of some claims suggests potential for innovative work that avoids infringement.
Key Takeaways
- Patent 9,205,059 protects aspects of biologic formulations, manufacturing processes, and therapeutic methods.
- Its claims are broad in process but specific in compositions, creating opportunities for design-around strategies.
- The patent landscape is highly active, with significant patenting related to biologics, especially regarding formulations and sequencing.
- Expiration timelines around 2030-2038 will influence market competition.
- Strategic R&D can focus on altering claim elements or advancing alternative formulations and manufacturing methods.
FAQs
-
What biological molecules are covered under Patent 9,205,059?
The patent targets protein therapeutics, specifically those with a defined amino acid sequence and formulation that enhances stability or bioavailability.
-
Can competitors develop similar biologics without infringing?
Yes. Altering amino acid sequences, formulations, or process steps described in the claims can avoid infringement.
-
Is the patent enforceable against biosimilar entrants?
Potentially, if biosimilars replicate the claimed formulations, sequences, or manufacturing methods, leading to infringement disputes.
-
How does this patent compare with other biologic patents?
It covers processes and formulations similar to contemporaneous patents but emphasizes specific stability-enhancing methods, aligning with common biologic patenting strategies.
-
When is the patent set to expire?
Expected between 2030 and 2038, considering standard 20-year term from the filing date (2012), subject to patent term adjustments.
References
[1] Smith, J. (2022). Trends in biologic patent litigation. Biotech Patent Review, 12(4), 33-45.
More… ↓
⤷ Start Trial
|
